[go: up one dir, main page]

Ferraris et al., 2013 - Google Patents

Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction

Ferraris et al., 2013

Document ID
8402227757614905013
Author
Ferraris G
Sidenius N
Publication year
Publication venue
Seminars in thrombosis and hemostasis

External Links

Snippet

The urokinase plasminogen activator receptor (uPAR) is a cell surface receptor involved in a multitude of physiologic and pathologic processes. uPAR regulates simultaneously a branch of the plasminogen activator system and modulates cell adhesion and intracellular signaling …
Continue reading at www.thieme-connect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general

Similar Documents

Publication Publication Date Title
Ferraris et al. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction
Ragno The urokinase receptor: a ligand or a receptor? Story of a sociable molecule
Emsley et al. Structure and function of factor XI
Kugler et al. Urokinase receptor and integrin interactions
Mazar et al. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis
Xu et al. Pathophysiological roles of cell surface and extracellular protein disulfide isomerase and their molecular mechanisms
Mazzieri et al. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration
Choudhri et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage
Del Zoppo Relationship of neurovascular elements to neuron injury during ischemia
Bekendam et al. Inhibition of protein disulfide isomerase in thrombosis
South et al. Conformational quiescence of ADAMTS‐13 prevents proteolytic promiscuity
Nylander et al. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action
EP1380290A1 (en) Cross-beta structure pathway and its therapeutic relevance
Matsumoto et al. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors
Bishop et al. Comparison of recombinant human thrombin and plasma-derived human α-thrombin
Suidan et al. The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin
Weisel et al. Mechanisms of fibrinolysis and basic principles of management
Kamikubo et al. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein
Gonias et al. Plasminogen receptors in human malignancies: Effects on prognosis and feasibility as targets for drug development
Kauskot et al. Hemostatic effects of recombinant DisBa-01, a disintegrin from Bothrops alternatus
Peng et al. tPA point mutation at autolysis loop enhances resistance to PAI-1 inhibition and catalytic activity
Takeyama et al. Protein S down‐regulates factor Xase activity independent of activated protein C: specific binding of factor VIII (a) to protein S inhibits interactions with factor IXa
Li et al. Recombinant factor VII a addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IX a/VIII a defect to rescue fibrin generation
SI22865A (en) Peptide uroaktivin as activator of enzyme urokinase
Inbal et al. Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: in vitro and ex vivo inhibition of platelet function